Close menu




October 23rd, 2019 | 07:54 CEST

AURORA, BEVCANNA, EXMCEUTICALS - CANADA GETTING READY FOR CANNABIS 2.0

  • Cannabis
Photo credits: pixabay.com

The consulting firm Deloitte has taken a close look at the cannabis industry and evaluated food and extracted products for the cannabis 2.0 market. In their analysis, the experts came to the conclusion that the annual Canadian market for food and alternative cannabis products is worth CAD 2.7 billion. The vast majority of this emerging cannabis 2.0 market will be products based on cannabis extracts, including foods, which the analysis puts at CAD 1.6 billion alone. But there are other significant opportunities, including cannabis-infused beverages with CAD 529 million, health products with CAD 174 million, concentrates with CAD 140 million, tinctures with CAD 116 million and capsules with CAD 114 million.

time to read: 1 minutes | Author: Mario Hose
ISIN:

Table of contents:


    LEGALIZATION PROVIDES FOUNDATION FOR NEW MARKETS

    The realisation of this considerable market potential will take some time, according to the Deloitte experts, because many cannabis products in these categories will only be available in sufficient quantities over time. Deloitte's industry representatives see cannabis 2.0 as a catalyst for the Canadian market, which is divided into two different target groups, in the context of further legalisation in October 2019.

    Firstly, experienced cannabis users, such as millennials and younger people, already consume cannabis several times a week and are open to new products.

    NEW CONSUMER GROUPS OFFER POTENTIAL

    As the second target group of a new cannabis boom, the Deloitte experts see the beginners and the curious. Usually they are not interested in flammable cannabis. This new conservative type of user, typically middle-aged and university educated, focuses on family needs or other responsibilities and consumes cannabis less than once a month.

    These consumers are expected to be attracted to more familiar formats, particularly foods such as baked goods, confectionery and teas. The low doses available in food and micro-doses are ideal for these consumers and provide a more convenient starting point for their cannabis experience.

    NEW COMPANIES OFFER FAVOURABLE VALUATIONS

    The outlined development of the cannabis 2.0 market becomes interesting in connection with the increasing legalization of cannabis products around the globe and against this background not only the first series like Aurora and Canopy Growth are exciting, but also the innovative new players with interesting business models or cost-efficient structures. In recent years, the young companies have been able to learn from the weaknesses and strengths of the already established billion-euro companies.

    BevCanna Enterprises Inc., a developer and manufacturer of cannabinoid-based beverages and consumer goods for private labels and white label customers, is just as interesting as EXMceuticals Inc., a company that produces CBD of the highest quality in various African countries and wants to offer it in large quantities worldwide. The two companies are currently valued at less than CAD 50 million on the stock exchange. Jonathan Summers, Chairman of EXMceuticals, will present the company this year at the German Equity Forum in Frankfurt. If Deloitte's market assessment proves to be true and this trend continues globally, then these two companies will certainly be attractively valued from today's perspective. We will see.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST

    BioNTech, XPhyto, Valneva - It is over!

    • Biotechnology
    • Covid19
    • Cannabis

    In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.

    Read

    Commented by Nico Popp on September 1st, 2022 | 14:05 CEST

    New trending stock in the wings? Plug Power, Cardiol Therapeutics, BioNTech

    • Biotechnology
    • Cannabis
    • Hydrogen

    The markets want to go up! Last Friday, the Fed shock worried the markets, but today, even speculative stocks are picking up again. Especially stocks that were long considered deregistered can quickly develop potential. One example is Plug Power. Here, new demand in the wake of high energy prices meets good products. We explain the secret to the success of comeback stocks, using Plug Power as an example, and highlight new opportunities.

    Read

    Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

    Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

    • Cannabis

    The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

    Read